These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 34257540)

  • 1. Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry.
    Huang RSP; Severson E; Haberberger J; Duncan DL; Hemmerich A; Edgerly C; Ferguson NL; Frampton G; Owens C; Williams E; Elvin J; Vergilio JA; Killian JK; Lin D; Morley S; McEwan D; Holmes O; Danziger N; Cohen MB; Sathyan P; McGregor K; Reddy P; Venstrom J; Anhorn R; Alexander B; Brown C; Ross JS; Ramkissoon SH
    Pathol Oncol Res; 2021; 27():592997. PubMed ID: 34257540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
    Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O
    Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548
    [No Abstract]   [Full Text] [Related]  

  • 4. Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.
    Huang RSP; Li X; Haberberger J; Sokol E; Severson E; Duncan DL; Hemmerich A; Edgerly C; Williams E; Elvin J; Vergilio JA; Killian JK; Lin D; Hiemenz M; Xiao J; McEwan D; Holmes O; Danziger N; Erlich R; Frampton G; Cohen MB; McGregor K; Reddy P; Cardeiro D; Anhorn R; Venstrom J; Alexander B; Brown C; Pusztai L; Ross JS; Ramkissoon SH
    Oncologist; 2020 Nov; 25(11):943-953. PubMed ID: 32869930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
    Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases.
    Huang RSP; Harries L; Decker B; Hiemenz MC; Murugesan K; Creeden J; Tolba K; Stabile LP; Ramkissoon SH; Burns TF; Ross JS
    Oncologist; 2022 Oct; 27(10):839-848. PubMed ID: 35598205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Prevalence of PD-L1 Expression Among Tumor Samples From Patients With Non-Small-Cell Lung Cancer.
    Gelatti ACZ; Cordeiro de Lima VC; Freitas H; Werutsky G; Gaiger AM; Klock C; Viola PP; Shiang C; de Macedo MP; Lopes LF; De Marchi P; Albino da Silva EC; Moura F; Borges G; Zaffaroni F; Nunes Filho PR; Araujo LH; Mascarenhas E; Mathias C; Barrios C; Zukin M
    Clin Lung Cancer; 2020 Nov; 21(6):e511-e515. PubMed ID: 32389509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
    Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
    Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data.
    Karatrasoglou EA; Chatziandreou I; Sakellariou S; Stamopoulos K; Kavantzas N; Lazaris AC; Korkolopoulou P; Saetta AA
    Virchows Arch; 2020 Aug; 477(2):207-217. PubMed ID: 31989260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations.
    Mei P; Shilo K; Wei L; Shen R; Tonkovich D; Li Z
    Cancer Cytopathol; 2019 Jul; 127(7):447-457. PubMed ID: 31025831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.
    Dietel M; Savelov N; Salanova R; Micke P; Bigras G; Hida T; Antunez J; Guldhammer Skov B; Hutarew G; Sua LF; Akita H; Chan OSH; Piperdi B; Burke T; Khambata-Ford S; Deitz AC
    Lung Cancer; 2019 Aug; 134():174-179. PubMed ID: 31319978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
    Liu J; Liu Y
    Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC).
    Jiang L; Su X; Zhang T; Yin X; Zhang M; Fu H; Han H; Sun Y; Dong L; Qian J; Xu Y; Fu X; Gavine PR; Zhou Y; Tian K; Huang J; Shen D; Jiang H; Yao Y; Han B; Gu Y
    Oncotarget; 2017 Apr; 8(16):26845-26857. PubMed ID: 28460468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.
    Mok TSK; Lopes G; Cho BC; Kowalski DM; Kasahara K; Wu YL; de Castro G; Turna HZ; Cristescu R; Aurora-Garg D; Loboda A; Lunceford J; Kobie J; Ayers M; Pietanza MC; Piperdi B; Herbst RS
    Ann Oncol; 2023 Apr; 34(4):377-388. PubMed ID: 36709038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.
    Omori S; Kenmotsu H; Abe M; Watanabe R; Sugino T; Kobayashi H; Nakashima K; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Ohde Y; Endo M; Akiyama Y; Nakajima T; Takahashi T
    Int J Clin Oncol; 2018 Dec; 23(6):1052-1059. PubMed ID: 29948239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 expression and its clinicopathologic and genomic correlation in the non-small cell lung carcinoma patients: An Indian perspective.
    Jain E; Sharma S; Aggarwal A; Bhardwaj N; Dewan A; Kumar A; Jain D; Bhattacharya M; Saurav GK; Kini L; Mohanty SK
    Pathol Res Pract; 2021 Dec; 228():153497. PubMed ID: 34053784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational Landscape and Expression of PD-L1 in Patients with Non-Small Cell Lung Cancer Harboring Genomic Alterations of the MET gene.
    Fischer A; Bankel L; Hiltbrunner S; Rechsteiner M; Rüschoff JH; Rushing EJ; Britschgi C; Curioni-Fontecedro A
    Target Oncol; 2022 Nov; 17(6):683-694. PubMed ID: 36136211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 Immunohistochemistry-Discrepant Results Between Synchronous Tumor Samples May Cause More Treatment Choice Dilemmas Than Molecular Heterogeneity in Patients With Advanced Non-Small Cell Lung Cancers.
    Lambros L; Quintin-Roué I; Bourhis A; Remoué A; Le Flahec G; Marcorelles P; Uguen A
    Appl Immunohistochem Mol Morphol; 2020 Jul; 28(6):437-443. PubMed ID: 31498156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
    Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL
    J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
    Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
    J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.